Home / Market News / $WVE

$WVE news and market catalysts

The 15 most recent market catalysts affecting $WVE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 3 high impact 4 bullish 5 bearish Gambling & Casinos
Nov 10, 2026 Corporate Catalyst Neutral Impact 60
Winvia Entertainment Completes Acquisition of The Online Giveaway Guys
Winvia Entertainment plc has finalized the acquisition of The Online Giveaway Guys (TOGG), an asset-only deal that strategically excludes TOGG's liabilities, cash, and trade receiv…
Nov 9, 2026 Corporate Catalyst Neutral Impact 55
B. Riley Securities Maintains Buy Rating for Wave Life Sciences
B. Riley Securities reaffirmed its 'Buy' rating for Wave Life Sciences, indicating continued confidence in the company's underlying business and clinical pipeline. However, the sim…
Nov 5, 2026 Corporate Catalyst Neutral Impact 65
Wave Life Sciences Outlines Pipeline Progress at 2026 Research Day
Wave Life Sciences held its 2026 Research Day, where it provided updates on its drug pipeline. The company announced its intention to file a Clinical Trial Application (CTA) for WV…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy Rating and Raises Price Target for Wave Life Sciences
Canaccord Genuity, an analyst firm, reiterated its 'Buy' rating for Wave Life Sciences and raised its price target by 4.8% to $44. This action signals continued confidence from a f…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Business Update
Wave Life Sciences reported a 73% increase in revenue year-over-year, which is a positive sign for growth. However, this was overshadowed by a wider net loss, driven by significant…
Oct 23, 2026 Corporate Catalyst Bullish Impact 85
Wave Life Sciences Reports Positive Phase 1 Data for WVE-007 and FDA Alignment for WVE-006
Wave Life Sciences reported positive interim Phase 1 data for WVE-007, an obesity treatment, demonstrating a 14.3% placebo-adjusted reduction in visceral fat. This is a significant…
Oct 16, 2026 Corporate Catalyst Neutral Impact 60
William Blair Initiates Coverage On Wave Life Sciences with Outperform Rating
William Blair, a well-known investment bank, has initiated coverage on Wave Life Sciences (WVE) with an Outperform rating. This is a positive development for WVE as it signals that…
Oct 15, 2026 Corporate Catalyst Neutral Impact 65
UBS Initiates Coverage On Wave Life Sciences with Buy Rating, Announces Price Target of $11
UBS analyst Joon Lee initiated coverage on Wave Life Sciences (WVE) with a 'Buy' rating and set an $11 price target. This event is significant because new analyst coverage, especia…
Oct 1, 2026 Corporate Catalyst Bullish Impact 75
Wave Life Sciences Plans For Two-Year Registrational Trial For WVE-006 To Treat Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has received positive feedback from the FDA regarding the registrational pathway for WVE-006, a drug targeting alpha-1 antitrypsin deficiency. This is a signific…
Sep 30, 2026 Corporate Catalyst Bullish Impact 75
Wave Life Sciences Announces $12M Milestone As GSK Selects Liver Disease Candidate For Development
This headline represents a significant positive catalyst for Wave Life Sciences (WVE), as the $12 million milestone payment provides non-dilutive capital and validates their propri…
Sep 23, 2026 Corporate Catalyst Bearish Impact 85
Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity.
The primary driver of the stock's movement is the JP Morgan downgrade from Overweight to Neutral. This signals a loss of confidence from a significant institutional investor, often…
Sep 23, 2026 Corporate Catalyst Bearish Impact 65
JP Morgan Downgrades Wave Life Sciences to Neutral
JP Morgan analyst Tessa Romero downgraded Wave Life Sciences (WVE) from an 'Overweight' rating to 'Neutral'. This change in rating indicates that the analyst no longer sees the sto…
Aug 4, 2026 Corporate Catalyst Bearish Impact 55
Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23
Mizuho analyst Salim Syed maintained an 'Outperform' rating for WAVE Life Sciences, signaling continued confidence in the company's long-term prospects. However, the reduction of t…
Jul 31, 2026 Corporate Catalyst Bearish Impact 55
Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12
Wedbush analyst Yun Zhong reiterated an 'Outperform' rating for WAVE Life Sciences (WVE) but simultaneously reduced the price target from $15 to $12. This action signals that while…
Jul 30, 2026 Corporate Catalyst Bearish Impact 95
WAVE Life Sciences Q2 EPS $(0.34) Misses $(0.31) Estimate, Sales $2.272M Miss $7.050M Estimate
WAVE Life Sciences announced Q2 earnings per share of $(0.34), missing the $(0.31) estimate by 9.68%, and sales of $2.272 million, missing the $7.050 million estimate by a substant…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.